Pulmatrix, which has pulled in tens of millions in venture capital from blue chip backers, has shown in lab tests that its inhaled dry power drug tech called iSperse beat a typical formulation of GlaxoSmithKline's ($GSK) big-selling treatment Advair in delivering "an effective therapeutic dose." The Lexington, MA-based firm--which was co-founded by MIT bioengineer extraordinaire Bob Langer--said that the results of the experiments have helped it move forward with development of the inhaled delivery tech in a variety of disease such as cystic fibrosis, pulmonary fibrosis and chronic obstructive pulmonary disease (COPD). Release